131Ⅰ治疗对甲状腺功能亢进患者心率变异性的影响

目的 观察甲状腺功能亢进(简称甲亢)患者心率变异性,探讨131Ⅰ治疗对甲亢患者自主神经功能的影响.方法 以哈尔滨医科大学附属第二医院和哈尔滨市第二医院就诊的56例甲亢患者作为观察对象,于131Ⅰ治疗前和治疗6个月后,进行12导联同步24 h动态监测,同时选取49例健康体检人员作对照组.观察指标包括24 h连续窦性R-R间期标准差(SDNN)、24 h连续5 min节段的窦性R-R间期标准差(SDANN)、24 h内两个相邻窦性R-R间期差>50 ms心率数占所分析信息期内的心率数的百分比(PNN50)、24 h连续窦性R-R间期差值的均方根(rMSSD)、极低频段功率(VLF)、低频段功率(LF)、高频段功率(HF)、低频段功率与高频段功率比值(LF/HF).结果 甲亢组治疗前SDNN[(85.25±13.59)ms]、SDANN[(95.47±33.15)ms]、PNN50[(15.26±4.84)%]、rMSSD[(14.47±3.49)ms]、LF[(435.57±75.74)ms2/Hz]、HF[(129.81±63.21)ms2/Hz]均明显低于对照组[(155.24±15.87)ms、(134.02±24.15)ms、(29.41±6.21)%、(26.64±6.11)ms、(515.69±74.83)ms2/Hz、(265.93±58.84)ms2/Hz,P均<0.05],VLF[(1765.21±315.22)ms2]、LF/HF(3.95±1.89)明显高于对照组[(374.25士54.47)ms2,2.94±1.55,P均<0.05],而甲亢组治疗后SDNN[(126.91±16.32)ms]、SDANN[(125.20±43.22)ms]、PNN50[(26.34±7.56)%]、rMSSD[(24.85±7.85)ms]、LF[(489.35-i-91.49)ms2/Hz]、HF[(209.45±75.32)ms2/Hz]均明显高于治疗前(P均<0.05),VLF[(571.80±97.41)ms2]、LF/HF比值(2.41±0.93)明显低于治疗前(P均<0.05),但与对照组相比较,SDNN、PNN50、HF仍明显降低,VLF明显增高,组间比较差异有统计学意义(P均<0.05).结论 甲亢患者心率变异性总体表现为降低,以交感神经活性占优势,应用131Ⅰ治疗可部分纠正心脏自主神经异常的病理生理现象.

Abstract：

Objective To observe the heart rate variability in patients with hypothyroidism, and to analyze the effect of 131Ⅰ therapy on autonomic nervous system of patients with the diseases. Methods A total of 56 cases of hyperthyroidism from the Second Affiliated Hospital of Harbin Medical University and the Second Hospital of Harbin City were enrolled as research subjects. 12-synchronous dynamic 24-hour monitoring and man-machine dialogue were used 6 months before and after 131Ⅰ treatment, and 49 cases of healthy volunteers were selected as controls.Heart rate variability indicators observed included 24 h consecutive sinus standard deviation of R-R interval (SDNN), standard deviation of sequential five-minute R-R interval (SDANN), percentage of differences between adjacent NN intervals that > 50 ms(PNN50), root mean square standard deviation from adjacent R-R interval (rMSSD), very low frequency power(VLF), low frequency power(LF), high frequency power(HF), and low frequency power/high frequency power(LF/HF). Results In hyperthyroidism group before 131Ⅰ therapy, SDNN[(85.25 ± 13.59)ms], SDANN [( 95.47 ± 33.15)ms], PNN50 [( 15.26 ± 4.84) %], rMSSD [( 14.47 ~ 3.49) ms], LF [(435.57 ± 75.74)ms2/Hz], and HF[(129.81 ± 63.21 )ms2/Hz] were significantly lower than those of the control group [(155.24 ±15.87), ( 134.02 ± 24.15)ms, (29.41 ± 6.21 )%, (26.64 ± 6.11 )ms, (515.69 ± 74.83)ms2/Hz, and (265.93 ± 58.84)ms2/Hz, all P < 0.05], VLF[(1765.21 ± 315.22)ms2] and LF/HF(3.95 ± 1.89) were significantly higher than that of the control group[(374.25 ± 54.47)ms2, 2.94 ± 1.55, all P < 0.05]. In hyperthyroidism group after treatment,SDNN [(126.91 ± 16.32)ms], SDANN[(125.2 ± 43.22)ms], PNN50[(26.34 ~ 7.56)%], rMSSD[(24.85 ± 7.85)ms],LF [(489.35 ± 91.49)ms2/Hz], and HF [(209.45 ± 75.32)ms] were also significantly higher than those before 131Ⅰ therapy, VLF[(571.80 ± 97.41)ms] and LF/HF(2.41 ± 0.93) were lower than that before 131Ⅰ therapy,but SDNN, PNN50 and HF were lower and VLF was higher than those of the control group (all P < 0.05). Conclusions The heart rate variability in patients with hyperthyroidism is lower in the overall performance, sympathetic activity is dominate, 131Ⅰ therapy partly corrects abnormal autonomic nerve function.